Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
Chrisann Kyi, MD
Advertisement
Chrisann Kyi, MD, is an assistant attending physician, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Articles by Chrisann Kyi, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zanubrutinib Plus Rituximab Receives FDA Priority Review in Frontline MCL
3
How Will Pancreatic, Prostate, and Endometrial Cancer Care Change by 2031?
4
Signatera ctDNA Test Shows Clinical Utility in Head and Neck Cancer
5